Paricalcitol Trial

About this trial

The trial is designed to establish whether adding a vitamin D analogue, Paricalcitol, to standard chemotherapy treatment, Gemcitabine and Nab-paclitaxel, can improve the outcomes for patients with advanced pancreatic cancer.

Patient Profile

Incurable recurrent, locally advanced or metastatic pancreatic adenocarcinoma.

Where’s this trial being run?

Beaumont Hospital, Cork University Hospital, Tallaght University Hospital, St Vincents University Hospital, University Hospital Limerick, and University Hospital Waterford

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: Paricalcitol Trial
Number: 19-33
Full Title:

Paricalcitol Trial: Phase II, Open label clinical trial of Paricalcitol in combination with Gemcitabine/ Nab-Paclitaxel therapy in advanced pancreatic cancer

Principal Investigator: Prof Bryan Hennessy (Beaumont)
Type: In-House

Cancer Trials Ireland

Recruitment Started: Global: October 2020
Ireland: October 2020
Global Recruitment Target: 43
Ireland Recruitment Target: 43